MedPath

UCB-Pharma SA

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

98

CIMA_AEMPS:57
NMPA:26
SFDA:9
+1 more agencies

Drug Approvals

Rozanolixizumab Injection

Product Name
优迪革
Approval Number
国药准字SJ20250012
Approval Date
Apr 25, 2025
NMPA

Bimekizumab Injection

Product Name
倍捷乐
Approval Number
国药准字SJ20240031
Approval Date
Jul 16, 2024
NMPA

Bimekizumab Injection

Product Name
倍捷乐
Approval Number
国药准字SJ20240030
Approval Date
Jul 16, 2024
NMPA

Rotigotine Patches

Product Name
优普洛
Approval Number
国药准字HJ20180026
Approval Date
Jul 13, 2023
NMPA

Rotigotine Patches

Product Name
优普洛
Approval Number
国药准字HJ20180027
Approval Date
Jul 13, 2023
NMPA

Rotigotine Patches

Product Name
优普洛
Approval Number
国药准字HJ20180029
Approval Date
Jul 13, 2023
NMPA

Rotigotine Patches

Product Name
优普洛
Approval Number
国药准字HJ20180028
Approval Date
Jul 13, 2023
NMPA

Cetirizine Dihydrochloride Tablets

Product Name
仙特明
Approval Number
国药准字HJ20171304
Approval Date
Nov 4, 2022
NMPA

Cetirizine Dihydrochloride Tablets

Product Name
仙特明
Approval Number
国药准字HJ20171303
Approval Date
Nov 4, 2022
NMPA

Levetiracetam Concentrated Solution for Injection

Product Name
开浦兰
Approval Number
国药准字HJ20170341
Approval Date
Apr 20, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.